Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial. - Wikidata - wikimedia - TriplyDB

Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.

Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.

http://www.wikidata.org/entity/Q35815286

about

Human Immunodeficiency Virus as a Chronic Disease: Evaluation and Management of Nonacquired Immune Deficiency Syndrome-Defining Conditions Micronutrient supplementation in adults with HIV infection.Vitamin D deficiency and altered bone mineral metabolism in HIV-infected individuals.Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate.Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent Trials Network Study 021B.High-dose vitamin D3 supplementation in children and young adults with HIV: a randomized, placebo-controlled trial.Increased bone resorption during tenofovir plus lopinavir/ritonavir therapy in Chinese individuals with HIV Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy.Bone health in HIV-infected children, adolescents and young adults: a systematic review.Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial.Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection.HIV and its effects on bone: a primer for rheumatologists Interventions to address chronic disease and HIV: strategies to promote exercise and nutrition among HIV-infected individuals.The protease inhibitors and HIV-associated bone loss.Tenofovir and bone health.Safety and Efficacy of High-Dose Daily Vitamin D3 Supplementation in Children and Young Adults Infected With Human Immunodeficiency Virus Bone health in children and adolescents with perinatal HIV infection Metabolic complications and treatment of perinatally HIV-infected children and adolescents.Prevalence and Factors Associated with Vitamin D Deficiency and Hyperparathyroidism in HIV-Infected Patients Treated in Barcelona.Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?Genetic associations with 25-hydroxyvitamin D deficiency in HIV-1-infected youth: fine-mapping for the GC/DBP gene that encodes the vitamin D-binding protein.Reporting of pre-enrolment screening with randomized clinical trials: A small item that could impact a big difference.Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIV.Associations of Low Vitamin D and Elevated Parathyroid Hormone Concentrations With Bone Mineral Density in Perinatally HIV-Infected Children.Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV.Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study.Effect of a monthly dose of calcidiol in improving vitamin D deficiency and secondary hyperparathyroidism in HIV-infected patients.Bone alterations associated with HIV.Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults with HIV Infection Being Treated with Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial.Continued Interest and Controversy: Vitamin D in HIV.

P2860

Q26740117-4726BA55-C6DB-44EC-8B10-0ADC2DBF2B17 Q33761301-BC663BAA-BC1E-43CD-AB71-538E8C688571 Q34016783-8352BFC5-663A-4C6F-A793-D274BB09FBAD Q34054004-C32214B7-1ED9-4EBC-895B-7883173C45DF Q34264297-89573ECD-6658-41F1-B7A5-8BF3B3EF38DB Q34799320-AD49ECA1-89F2-4A33-B3F5-3BC28DA5B9CB Q35102114-C0421737-2467-403C-ADE9-0CA994427409 Q35659264-5D077D90-E204-45FE-8A2E-A22D4AC19F55 Q35822412-A2A1CE6B-2410-43CE-960E-54FC790B8EC5 Q36170370-F04FA584-2137-4819-ACDE-A9BA06C28D74 Q36361380-88E41742-8FFF-4C2B-A683-985279D58CAC Q36381079-A327AAC8-D873-4110-8141-E711A1B5B425 Q36381307-06DD119C-ED1F-4767-8149-6180962DEF22 Q36818259-D02D53CD-DFE2-45C3-A88C-72168E67DFF3 Q36833961-E34E2AF5-E910-4452-BBE4-8EC237D5B0FF Q36862311-81182F36-25CA-474E-912E-83EBBCFA1A31 Q36941678-1A305168-D91F-40BC-846F-F6A0A956757D Q36952291-DEC2F356-2219-442B-A830-674927EE52DE Q37156878-52890C66-56FD-495E-B563-A5EB17D4BC2B Q37263395-38FFED95-BC54-4872-B01E-4E0B22FC7F43 Q37307158-B7D2224F-D538-4A9F-9307-21E78816EBFC Q38979133-BFCD7189-C0CC-45F9-8D36-25D4B32FDCD2 Q39813500-5998C0A5-5D95-4099-B64F-B66B1F13CCA2 Q40087344-5847425D-2A56-4578-A5C5-D9955FB4259A Q40396204-FC872AAB-4704-4F28-95F3-F97DAC1BFB39 Q40874258-466EA567-6941-4152-B0A9-67189DCC12AF Q41056086-22DEFA26-FFEE-4412-805E-03BF62F652DA Q41644519-5304ACB8-A9C5-4812-9B18-A28360FCC704 Q42203594-198755EA-1BAE-47CF-97E7-555429F9818C Q46099287-F1044E51-C3F5-43E4-8E7C-40F050D38F2A Q54224147-24C417AC-55C1-4FC2-9FC2-214E79F0F622

P2860

Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.

http://www.wikidata.org/entity/Q35815286

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Vitamin D3 decreases parathyro ...... zed, placebo-controlled trial.

@ast

Vitamin D3 decreases parathyro ...... zed, placebo-controlled trial.

@en

type

label

Vitamin D3 decreases parathyro ...... zed, placebo-controlled trial.

@ast

Vitamin D3 decreases parathyro ...... zed, placebo-controlled trial.

@en

prefLabel

Vitamin D3 decreases parathyro ...... zed, placebo-controlled trial.

@ast

Vitamin D3 decreases parathyro ...... zed, placebo-controlled trial.

@en

P1433

Q35815286-1347E656-E46E-4C89-B4FA-72084450580F

P1476

Q35815286-0CEBF2CB-EE9F-4748-8FE4-3BADDB460EF4

P2093

Q35815286-0A4462D6-A174-4E92-9BD3-0E80AFE361C5

Q35815286-0B9AE574-8574-40D4-AAC1-96F84FF05678

Q35815286-197FE521-3A77-4A74-9717-B55EDB85740C

Q35815286-1D7BF48F-03C9-46B7-B4B8-D84412183220

Q35815286-50C98086-44B9-4B3A-9541-E1F828EB9649

Q35815286-647E9108-CE00-4FF8-AA23-6932606BE264

Q35815286-739A8C24-246C-4249-8E14-506249EC93AC

Q35815286-7761F1F6-66EF-4047-8FE2-A654E9DE4111

Q35815286-8105C329-2D40-426E-AD33-CF4B00D568A5

Q35815286-8885AE6A-E40C-47BC-AEE0-BA9A402F2DE8

P2860

Q35815286-1DC7A555-8632-42DA-9520-6A08E2927B3C

Q35815286-257CE846-67A1-4C92-AE8F-33A065AB03F9

Q35815286-26173D63-7924-4C66-8F08-8FC69F68879D

Q35815286-2F7CDA9E-2ED4-43EA-B443-725CB7F0705E

Q35815286-357AEE49-FD71-4781-B0E3-31D222ADF8F4

Q35815286-3C47053C-A46A-49F7-9748-40EC0BB952AB

Q35815286-40482F3F-DABC-4FB1-A309-0404F69A9A07

Q35815286-462AD4F8-33F1-4289-978C-3EB49B607C4E

Q35815286-4D5C63FD-79CA-437E-BE15-52948B572110

Q35815286-4DBBFDF6-BC43-449F-A1A1-9BE0013BEB98

P304

Q35815286-8682CD40-D7AD-4371-A5C9-6C6B1BFE881E

P31

Q35815286-5DD83402-1562-4D1B-8E3B-2A4BD3BD91F2

P356

Q35815286-B9A33DA4-B2E7-49AA-AF6A-247A2090CD6A

P407

Q35815286-C664F474-FCA9-47A6-B25F-4B461429377F

P433

Q35815286-88DD36D6-897A-4A90-BDDB-62B777BC065A

P478

Q35815286-3C612B3F-8D8D-4750-8730-ED2F6334BEA4

P577

Q35815286-5F4A1978-B8DA-4318-872A-08D4F6DEB820

P5875

Q35815286-E7D5676A-49A3-4262-A70E-E647DAF38837

P698

Q35815286-5FDFDDD5-06C3-41D7-B3E9-359AB4DC31DD

P921

Q35815286-A658BD37-733D-4481-B93A-2DD84B1A647C

P932

Q35815286-E6906C94-78E7-49A4-8758-597335F6BD44

P356

P1433

Clinical Infectious Diseases

P1476

Vitamin D3 decreases parathyro ...... zed, placebo-controlled trial.

@en

P2093

Adolescent Medicine Trials Network (ATN) for HIV/AIDS Interventions 063 study team

http://www.w3.org/2001/XMLSchema#string

Alyne Baker

http://www.w3.org/2001/XMLSchema#string

Bill G Kapogiannis

http://www.w3.org/2001/XMLSchema#string

Brandy Rutledge

http://www.w3.org/2001/XMLSchema#string

Charles B Stephensen

http://www.w3.org/2001/XMLSchema#string

Craig M Wilson

http://www.w3.org/2001/XMLSchema#string

Cynthia G Pan

http://www.w3.org/2001/XMLSchema#string

James Bethel

http://www.w3.org/2001/XMLSchema#string

Jorge Lujan-Zilbermann

http://www.w3.org/2001/XMLSchema#string

Kathleen Mulligan

http://www.w3.org/2001/XMLSchema#string

P2860

The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis

Vitamin D deficiency

Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study

Tenofovir-associated bone density loss.

Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.

Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss

Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users

Vitamin D2 is much less effective than vitamin D3 in humans.

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate.

25-Hydroxylation of vitamin D3: relation to circulating vitamin D3 under various input conditions.

P304

1013-1025

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIR968

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221768735

http://www.w3.org/2001/XMLSchema#string

P698

22267714

http://www.w3.org/2001/XMLSchema#string

P921

P932

3297650

http://www.w3.org/2001/XMLSchema#string